Drug resistant Mycobacterium tuberculosis in Mexico

Journal of Infection in Developing Countries

Volumn 3, Issue 3, 2009, Pages 162-168

  Zazueta Beltran, Jorge ^a   León Sicairos, Claudia ^b   Canizalez Roman, Adrián ^a,b  

^a Secretary of Health   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SINALOA   (Mexico)

Author keywords

Drug; Mexico; Mycobacterium; Resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

BACTERIAL STRAIN; DRUG COST; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; HUMAN; LUNG TUBERCULOSIS; MEDICAL INFORMATION SYSTEM; MEXICO; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; REVIEW; SHORT COURSE THERAPY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MEXICO; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 67649518356     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.31     Document Type: Review

References (43)

1. Gleissberg V (1999) The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable? Lancet 353: 998-999.
2. Kochi A, Vareldzis B, Styblo K (1993) Multidrug-resistant tuberculosis and its control. Res Microbiol 144: 104-110.
3. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328: 521-526.
4. García-García ML, Sifuentes-Osornio J, Jiménez-Corona ME et al. (2001) Resistencia de Mycobacterium tuberculosis a los antimicrobianos en Orizaba, Veracruz. Implicaciones para el programa de prevención y control de la tuberculosis. Rev Invest Clin 53: 315-323.
5. Laszlo A, de Kantor IN (1994) A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ 72:603-610.
6. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006 55: 301-305.
7. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva, Switzerland. Report WHO/TB/97220 1997.
8. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Jama 283: 2537-2545.
9. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, Palacios-Martinez M, Martinez-Gamboa A, Small PM, Sifuentes-Osomio J, Ponce-de-Leon A (2005) Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365: 1239-1245.
10. Espinal MA, Dye C (2005) Can DOTS control multidrug-resistant tuberculosis? Lancet 365: 1206-1209.
11. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, Jimenez-Corona A, Palacios-Martinez M, Balandrano-Campos S, Ferreyra-Reyes L, Juarez-Sandino L, Sifuentes-Osomio J, Olivera-Diaz H et al. (2000) Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 160: 630-636.
12. World Health Organization. WHO Report on the Tuberculosis Epidemic. WHO/ TB/97/224. Geneva: WHO. 1997.
13. Estimates of future global tuberculosis morbidity and mortality. MMWR Morb Mortal Wkly Rep 1993, 42:961-964.
14. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama 282: 677-686.
15. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2007 Geneva, Switzerland, WHO/HTM/TB/ 2007376.
16. Baez-Saldana AR, Perez-Padilla JR, Salazar-Lezama MA (2003) [Epidemiology of Tuberculosis in Mexico, 1981-1998. Inconsistencies between reports of the WHO and the Ministry of health.]. Salud Publica Mex, 45:78-83.
17. Caminero Luna JA Origen, (2001) Presente y futuro de las resistencias en tuberculosis. Arch Bronconeumol 37:35-42.
18. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344: 1294-1303.
19. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 338: 1641-1649.
20. WHO/IUATLD Global Proyect on Antituberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report 2: Prevalence and trends. WHO/CDC/TB/2000.278. Geneva. WHO, 2000.
21. WHO/IUATLD Global Proyect on Antituberculosis. Drug Resistance Surveillance 1999-2002. Anti-tuberculosis drug resistance in ther world. Third Global Report. WHO/CDC/TB/2004.343. Geneva, Switzerland. WHO, 2004.
22. WHO/IUATLD Global Proyect on Antituberculosis. Drug Resistance Surveillance 2002-2007. Anti-tuberculosis drug resistance in the world. Four Global Report. WHO/HTM/TB/2008.394. Geneva, Switzerland. WHO, 2008.
23. Tapia R, Ruiz C, Ferreira E: Epidemiología de la tuberculosis en México. En: Sada E, Sifuentes J eds. Tuberculosis. México. MCGraw-Hill Interamericana editores. México. 1995: 761-788.
24. Secretaría de Salud. Modificación a la Norma Oficial Mexicana NOM-006-SSA2-1993. Para la prevención y control de la tuberculosis en la atención primaria a la salud.. Diario Oficial de la Federación, 2000. Octubre: 9-33.
25. Granich RM, Balandrano S, Santaella AJ, Binkin NJ, Castro KG, Marquez-Fiol A, Anzaldo G, Zarate M, Jaimes ML, Velazquez-Monroy O, et al. (2000) Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med (160: 639-644.
26. Zazueta-Beltran J, Muro-Amador S, Flores-Gaxiola A, Llausas-Magana E, Leon-Sicairos N, Canizalez-Roman A (2007) High rates of multidrug-resistant Mycobacterium tuberculosis in Sinaloa State, Mexico. J Infect 54: 411-412.
27. Fragoso Morales LE, Pastor Durango P, Magana Aquino M, Fajardo Santana H, Bobadilla de Valle M, Carrera de la Torre B, Ramirez Flores B, Sifuentes Osornio J: [Risk factors for drug-resistant tuberculosis in San Luis Potosi, Mexico 2003-2004]. Salud Publica Mex 2006, 48: 361-362.
28. Sifuentes Osomio J (2003) Epidemiología de la resistencia antimicrobiana en Mycobacterium tuberculosis en México. Gac Méd Méx 139: 477-480.
29. Olvera Castillo R (2001) Farmacorresistencia secundaria en tuberculosis. Tendencia en el Instituto Nacional de Enfermedades Respiratorias. Rev Inst Nal Enf Resp Mex 14: 151-159.
30. Velasco-Rodriguez VM, Padua-Gabriel A, Esquivel-Molina C, Sanchez-Cabral O, Martinez-Ordaz V, Cicero-Sabido R (2004) Epidemiología y resistencia primaria a farmacos en casos incidentes de tuberculosis pulmonar. Rev Med IMSS 42: 301-306.
31. Amaya-Tapia G, Martin-Del Campo L, Aguirre-Avalos G, Portillo-Gomez L, Covarrubias-Pinedo A, Aguilar-Benavides S (2000) Primary and acquired resistance of Mycobacterium tuberculosis in Western Mexico. Microb Drug Resist, 6:143-145.
32. Garcia-Garcia ML, Jimenez-Corona ME, Ponce-de-Leon A, Jimenez-Corona A, Palacios-Martinez M, Balandrano-Campos S, Ferreyra-Reyes L, Juarez-Sandino L, Sifuentes-Osornio J, Olivera-Diaz H, et al (2000) Mycobacterium tuberculosis drug resistance in a suburban community in southem Mexico. Int J Tuberc Lung Dis, 4:S 168-170.
33. Said-Fernandez S, Caballero-Olín G, Becerril-Montes P, Navarro-Marmolejo L, Valdovinos-Chavez S (2001) Perfiles de Resistencia a Medicamentos Antituberculosos de Primera y Segunda Elección en Cepas de Mycobacterium Tuberculosis Aisladas de Enfermos con Tuberculosis Pulmonar Radicados en el Sector Noroeste de la Ciudad de Monterrey y Atendidos por el IMSS. Revista de Salud Publica y Nutricion, 4.
34. Bernal-Alvarado KS, Herrera N, Pizarro-Chavez S, Grimaldo-Zuñiga N, Rivera-Chavira BE (2002) Frecuencia de Resistencia Primaria de Cepas de M. Tuberculosis Aisladas de Pacientes de la Ciudad de Chihuahua. Revista de Salud Publica y Nutricion, 5.
35. Martinez-Medina MA (2004) [Effect of shortened directly observed treatment on compliance and cure rate of pulmonary tuberculosis]. Gac Med Mex, 140: 1-6.
36. Salazar-Lezama MA, Torres-Cruz A, Valdez-Vazquez RR, Lopez-Segundo E, Villareal-Velarde H, Quiñonez-Falconi F, Baez-Saldaña R (2004) Resultados de Tratamiento de Tuberculosis Resistente en 91 Pacientes del Instituto Nacional de Enfermedades Respiratorias: 2001-2003. Revista Instituto Nacional de Enfermedades Respiratorias, 17:15-21.
37. Herrera TM, Blancarte ML, Anzaldo JG, Campos BL, Santíes VR (1976) Resistencias primarias en 126 casos de tuberculosis pulmonar. Salud Publica Mex 16: 111-114.
38. Blancarte ML, Anzaldo JG, Balandrano SS (1982) Resistencia primaria de Mycobacterium tuberculosis. Salud Publica Mex 24: 321-327.
39. Secretaria de Salud. Subsecretaria de coordinación y desarrollo. Instituto Nacional de Diagnóstico y Referencia Epidemiológicos. Resumen de actividades 1980-1994. México. 1994. 1994.
40. Alvarez-Gordillo GC, Halperin-Frisch D, Blancarte-Melendres L, Vazquez-Castellanos J (1995) Factores de riesgo para resistencia a drogas antifimicas en Chiapas, México. Salud Publica Mex 37: 408-416.
41. Sifuentes-Osornio J, Ponce-de-Leon LA, Camacho-Mezquita FE, Bobadilla-del-Valle JM, Infante-Suarez ML, Ramirez-Fernandez N, Hernandez-Gomez L, Nelson AM (1995) [Resistance of Mycobacterium tuberculosis in Mexican patients. I. Clinical features and risk factors]. Rev Invest Clin 47: 273-281.
42. Peter CR, Schultz E, Moser K, Cox M, Freeman R, Ramirez-Zetina M, Lomeli MR (1998) Drug-resistant pulmonary tuberculosis in the Baja California-San Diego County border population. West J Med 169: 208-213.
43. Laniado-Laborin R, Cabrales-Vargas N (2000) Tratamiento acortado estrictamente supervisado: Estrategia necesaria, pero no suficiente para controlar la tuberculosis en Baja, California, México. Rev Inst Nal Enf Resp Mex 13:23-27.